Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.

Niziolek PJ, Farmer TL, Cui Y, Turner CH, Warman ML, Robling AG.

Bone. 2011 Nov;49(5):1010-9. doi: 10.1016/j.bone.2011.07.034. Epub 2011 Aug 9.

PMID:
21855668
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

High bone mass in mice expressing a mutant LRP5 gene.

Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F.

J Bone Miner Res. 2003 Jun;18(6):960-74.

PMID:
12817748
[PubMed - indexed for MEDLINE]
3.

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.

Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R.

J Bone Miner Res. 2006 Nov;21(11):1738-49.

PMID:
17002572
[PubMed - indexed for MEDLINE]
4.

Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.

Bhat BM, Allen KM, Liu W, Graham J, Morales A, Anisowicz A, Lam HS, McCauley C, Coleburn V, Cain M, Fortier E, Bhat RA, Bex FJ, Yaworsky PJ.

Gene. 2007 Apr 15;391(1-2):103-12. Epub 2006 Dec 29.

PMID:
17276019
[PubMed - indexed for MEDLINE]
5.

Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner.

Niziolek PJ, Warman ML, Robling AG.

Bone. 2012 Sep;51(3):459-65. doi: 10.1016/j.bone.2012.05.023. Epub 2012 Jun 28.

PMID:
22750014
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Bone biomechanical properties in LRP5 mutant mice.

Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, Haynatzki GR, Babij P, Allen KM, Yaworsky PJ, Bex F, Recker RR.

Bone. 2004 Jul;35(1):162-9.

PMID:
15207752
[PubMed - indexed for MEDLINE]
7.

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.

Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W.

Calcif Tissue Int. 2008 Jun;82(6):445-53. doi: 10.1007/s00223-008-9130-9.

PMID:
18521528
[PubMed - indexed for MEDLINE]
8.

Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5.

Lee GS, Simpson C, Sun BH, Yao C, Foer D, Sullivan B, Matthes S, Alenina N, Belsky J, Bader M, Insogna KL.

J Bone Miner Res. 2014 Apr;29(4):976-81. doi: 10.1002/jbmr.2086.

PMID:
24038240
[PubMed - in process]
9.

Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG.

Sci Transl Med. 2013 Nov 13;5(211):211ra158. doi: 10.1126/scitranslmed.3006627.

PMID:
24225945
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.

Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, van Hul W, Eastell R, Kassem M, Brixen K.

J Bone Miner Res. 2011 Aug;26(8):1721-8. doi: 10.1002/jbmr.376.

PMID:
21351148
[PubMed - indexed for MEDLINE]
11.
12.

LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.

Semenov MV, He X.

J Biol Chem. 2006 Dec 15;281(50):38276-84. Epub 2006 Oct 19.

PMID:
17052975
[PubMed - indexed for MEDLINE]
Free Article
13.

Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.

Simpson CA, Foer D, Lee GS, Bihuniak J, Sun B, Sullivan R, Belsky J, Insogna KL.

Osteoporos Int. 2014 Jun 14. [Epub ahead of print]

PMID:
24927689
[PubMed - as supplied by publisher]
14.

An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations.

Ayturk UM, Jacobsen CM, Christodoulou DC, Gorham J, Seidman JG, Seidman CE, Robling AG, Warman ML.

J Bone Miner Res. 2013 Oct;28(10):2081-93. doi: 10.1002/jbmr.1946.

PMID:
23553928
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.

Korvala J, Jüppner H, Mäkitie O, Sochett E, Schnabel D, Mora S, Bartels CF, Warman ML, Deraska D, Cole WG, Hartikka H, Ala-Kokko L, Männikkö M.

BMC Med Genet. 2012 Apr 10;13:26. doi: 10.1186/1471-2350-13-26.

PMID:
22487062
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.

Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, Ettenberg SA, Cong F, Halleux C, Kneissel M.

J Bone Miner Res. 2014 Jan;29(1):29-42. doi: 10.1002/jbmr.2059.

PMID:
23901037
[PubMed - in process]
17.

Targeting the LRP5 Pathway Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta.

Jacobsen CM, Barber LA, Ayturk UM, Roberts HJ, Deal LE, Schwartz MA, Weis M, Eyre D, Zurakowski D, Robling AG, Warman ML.

J Bone Miner Res. 2014 Feb 12. doi: 10.1002/jbmr.2198. [Epub ahead of print]

PMID:
24677211
[PubMed - as supplied by publisher]
18.

The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd.

Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, Zheng J, Li L, Harris S, Wu D.

Mol Cell Biol. 2004 Jun;24(11):4677-84.

PMID:
15143163
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.

Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML.

Mol Cell Biol. 2005 Jun;25(12):4946-55.

PMID:
15923613
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.

Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y.

Development. 2008 Nov;135(22):3801-11. doi: 10.1242/dev.025825. Epub 2008 Oct 16.

PMID:
18927151
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk